Patent Issued for SOD1 dual expression vectors and uses thereof (USPTO 11739330).

The rAAV of claim 12, wherein the capsid protein is AAV9 capsid protein or AAVrh.10 capsid protein. Keywords: Bioengineering; Biotechnology; Capsid; Dismutase; Drugs and Therapies; Engineering; Enzymes and Coenzymes; Gene Therapy; Genetics; Nucleocapsid; Nucleocapsid Proteins; Risk and Prevention; University of Massachusetts; Viral Proteins; Viral RNA; Virions; miRNA-Based Therapy EN Bioengineering Biotechnology Capsid Dismutase Drugs and Therapies Engineering Enzymes and Coenzymes Gene Therapy Genetics Nucleocapsid Nucleocapsid Proteins Risk and Prevention University of Massachusetts Viral Proteins Viral RNA Virions miRNA-Based Therapy 3619 3619 1 09/19/23 20230918 NES 230918 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent by the inventors Brown, Robert H. (Needham, MA, US), Mueller, Christian (Concord, MA, US), filed on September 21, 2018, was published online on August 29, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. The isolated nucleic acid of claim 1, wherein the exogenous mRNA encoding the SOD1 protein has one or more silent base pair mutations relative to the endogenous mRNA. [Extracted from the article]